1510832-11-7

Basic information

• Product Name: C₃₅H₄₂N₆O₁₂S₂
• Synonyms: C₃₅H₄₂N₆O₁₂S₂
• CAS NO: 1510832-11-7
• Molecular Weight: 802.883
• Mol File: 1510832-11-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₃₅H₄₂N₆O₁₂S₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₅H₄₂N₆O₁₂S₂(1510832-11-7)
• EPA Substance Registry System: C₃₅H₄₂N₆O₁₂S₂(1510832-11-7)

Safety Data

• Hazardous Substances Data: 1510832-11-7(Hazardous Substances Data)

Upstream product

• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 63088-78-8 (2S,5R)-5-hydroxypiperidine-2-carboxylic acid 
• 1510832-15-1 (1S,4S)-5-((2-nitrophenyl)sulfonyl)-2-oxa-5-azabicyclo[2.2.2]octan-3-one 
• 1033774-90-1 N-4-nitrobenzene sulfonyl-O-benzylhydroxylamine 
• 1510832-18-4 tert-butyl 4-((2S,5S)-1-((2-nitrophenyl)sulfonyl)-5-(((2-nitrophenyl)sulfonyl)oxy)piperidine-2-carboxamido)piperidine-1-carboxylate 

Downstream Products

• 1510832-19-5 4-((2S,5R)-((benzyloxy)amino)piperidine-2-carboxamido)piperidine-1-carboxylic acid tert-butyl ester 
• 1174020-63-3 tert-butyl 4-((1R,2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate 
• 1174018-99-5 (2S,5R)-sulfuric acid mono{[(4-aminopiperidin-4-yl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl}ester 
• 1510831-80-7 C₃₁H₄₂N₄O₈S₂ 
• 1510831-81-8 C₃₅H₄₄N₄O₆S₂ 

Relevant articles and documents

PREPARATION OF TERT-BUTYL 4-((1R,2S,5R)-6- (BENZYLOXY)-7-0X0-1,6-DIAZABICYCL0[3.2.I]OCTANE-2- CARBOXAMIDO)PIPERIDINE-1-CARBOXYLATE

A process for the preparation of N-protected 6-(piperidin-4-ylcarbamoyl)piperidin-3-yl sulfonates of Formula (III): which comprises contacting a lactone of Formula (II): with an azacycloalkylamine of formula (II-Am): followed by contact with a sulfonyl halide of formula (II-Su): R4-SO2W (II-Su) in the presence of tertiary amine base, wherein PG1 and PG2 are amine protective groups; k, p and q are 0, 1, or 2, and W, R2, R3, R4, R5, R6, R7, R8, and R9 are defined herein. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as β-lactamase inhibitors.